Amsterdam, The Netherlands, May 7, 2015 – Kiadis Pharma B.V. (“Kiadis Pharma” or “the Company”), a clinical stage biopharmaceutical company developing innovative immunotherapy treatments, today announces the appointment of Dr. Vincent Brichard as an independent member of its Supervisory Board.
Dr. Brichard has more than 25 years’ experience in the oncology and immunology field, including almost 15 years at GlaxoSmithKline (“GSK”) where he was Senior Vice-President and had responsibility for the Immunotherapeutics Business Unit, which covered a broad, integrated approach to immunotherapy – from bench discovery through clinical development and operations to regulatory and commercial activities. In addition to this position, he served as a member of the Board of Directors at GSK Biologicals. Dr. Brichard is a physician by training and holds a PhD in tumor immunology. He began his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. He further holds an MBA from the Harvard Business School.
Manfred Rüdiger, CEO of Kiadis Pharma, commented: “We are very pleased to have attracted someone of Dr. Brichard’s caliber to the Board. His strong background and successful career in oncology and immunology will complement the Company’s already strong team and network. We look forward to benefiting from his counsel.”
Dr. Vincent Brichard commented: “With my background in oncology and immunology, my work has been focused since 1986 on the appealing project of educating our natural defenses – those that protect us from infectious diseases – to recognize and kill cancer cells. ATIR™ achieved some extremely compelling clinical data and the Phase II study interim analysis in December demonstrated the drug’s true potential as an adjunctive life-saving therapy for blood cancer patients. I am looking forward to joining the Board and working with the team to develop ATIR™ to its full potential.”
